Trial Profile
The Efficacy of Orally Administered GSK2190915 as an Add-on to Current Therapy in Subjects With Moderate to Severe Asthma Who Have Elevated Sputum Neutrophils.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Aug 2023
Price :
$35
*
At a glance
- Drugs Fiboflapon (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GSK
- 11 Mar 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 09 Jul 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 09 Jul 2010 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.